Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.